Joon Yun
Overview
Palo Alto Investors, founded in 1989, is a hedge fund specializing in healthcare investments, focusing on pharmaceutical, medical device, and biotechnology sectors. The firm manages approximately $1 billion in assets, primarily invested in these areas. Dr. Joon Yun, a board-certified radiologist, joined the firm in 1998 and became its president in 2008. He holds a B.A. from Harvard University and an M.D. from Duke University School of Medicine. Prior to his investment career, Dr. Yun served on the clinical faculty at Stanford Hospital from 2000 to 2006. Under his leadership, Palo Alto Investors has maintained a strong track record in healthcare investments. The firm's investment strategy emphasizes identifying undervalued companies within the healthcare sector, leveraging Dr. Yun's clinical expertise and industry experience to evaluate potential investments effectively. This approach has enabled the firm to achieve significant returns by capitalizing on market inefficiencies and emerging opportunities in the healthcare industry. Dr. Yun's unique combination of medical and financial expertise continues to drive the firm's success in the competitive hedge fund landscape.
Investment Focus
- Strong growth potential
- Experienced management team
- Innovative products or services
- Competitive market position
Portfolio Companies
Reach Joon Yun directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Joon Yun
What sectors does Joon Yun invest in?
Joon Yun invests in Healthcare, Pharmaceuticals, Medical Devices and Biotechnology, and is based in California, United States. Joon Yun is listed as a hedge fund in the ConnectSafely investor database.
What stage does Joon Yun invest at?
Joon Yun backs companies at Growth, Late Stage and Pre-IPO, writing cheques of 10M - 50M.
Which regions does Joon Yun invest in?
Joon Yun invests across United States.
What companies has Joon Yun invested in?
Joon Yun's portfolio includes Biogen, Amgen, Gilead Sciences, Regeneron Pharmaceuticals and Aimmune Therapeutics.
Last updated · Source: ConnectSafely investor database
